Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details
Interested parties may participate in the call by dialing:
(877) 407-6176 (US Toll-Free)
+1 (201) 689-8451 (International)
Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=4jnXGdPH
Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.
For further information, please contact:
Investor Relationsir@viemed.com
Tripp SullivanSCR Partners, LLC615-942-7077
Trae FitzgeraldChief Financial OfficerViemed Healthcare, Inc.337-504-3802
SOURCE: Viemed Healthcare, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
MBX Biosciences Submits IND for Once-Monthly Obesity Drug
MBX Biosciences Inc. (NASDAQ:MBX) is one of the best IPO stocks to buy according to Wall Street analysts. On June 16, MBX Biosciences announced the submission of an Investigational New Drug/IND application to the US FDA for MBX 4291. This drug is a long-acting GLP-1/GIP receptor co-agonist prodrug being developed for the treatment of obesity. The company's President and CEO, Kent Hawryluk, stated that MBX 4291 is designed to be a potential once-monthly injectable, which could offer less frequent dosing and improved gastrointestinal tolerability, potentially leading to better patient adherence and increased weight loss. MBX 4291 was created using the company's proprietary Precision Endocrine Peptide/PEP platform. A doctor holding a test tube of the biopharmaceutical company's NicAlert drug product while providing patient care. In preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss as tirzepatide, a weekly GLP-1/GIP co-agonist that is already approved. Furthermore, these preclinical studies showed an extended duration of action for MBX 4291's active component compared to tirzepatide, supporting the potential for once-monthly administration. MBX Biosciences Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company that discovers and develops precision peptide therapies for the treatment of endocrine and metabolic disorders. While we acknowledge the potential of MBX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
New Tesla, Nvidia Funds Offer Leveraged Bets
Leverage Shares by Themes offers single-stock funds tied to popular names like Tesla Inc. and Nvidia Corp. that use options to deliver monthly leverage that matches a stock's declines rather than magnify them. Bloomberg's Vildana Hajric reports. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
3 hours ago
- Business Insider
Guggenheim Remains a Buy on Nexstar Media Group (NXST)
In a report released today, Curry Baker from Guggenheim maintained a Buy rating on Nexstar Media Group, with a price target of $250.00. The company's shares closed today at $207.73. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Baker covers the Communication Services sector, focusing on stocks such as Liberty Media Liberty Formula One, Liberty Media Liberty Formula One, and Live Nation Entertainment. According to TipRanks, Baker has an average return of 12.4% and a 64.17% success rate on recommended stocks. In addition to Guggenheim, Nexstar Media Group also received a Buy from Barrington's Patrick Sholl in a report issued today. However, on August 15, Citi maintained a Hold rating on Nexstar Media Group (NASDAQ: NXST).
